Roivant Sciences Ltd. (NASDAQ:ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the commencement of a proposed underwritten public offering of $150,000,000 of common shares. Roivant expects to grant the underwriter a 30-day option to purchase up to $22.5 million of additional common shares. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Burford Capital Expands And Further Extends Sovereign Wealth Fund Arrangement
Burford Capital Limited ("Burford"), the leading global finance and asset management firm focused on law, today announces the expansion and further extension of its funding arrangement ("BOF-C")
